Emergent BioSolutions Inc. (NYSE:EBS) will look for M&A. Chief Executive Officer Robert Kramer said, "We continue to be focused on looking opportunistically at M&A transactions that are strategically on point for the proper value. We continue to build scalable capability across our enterprise to be able to efficiently grow as we go forward. Always looking for opportunities to strengthen our R&D portfolio and of paramount importance is continuing to strengthen our overall culture in the company".
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.11 USD | +7.07% |
|
+38.88% | +404.58% |
07-09 | Emergent Biosolutions, Johnson & Johnson Settle Dispute Over COVID-19 Vaccine Manufacturing | MT |
07-08 | Emergent, J&J settle COVID vaccine supply deal dispute | RE |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+404.58% | 635M | |
+61.53% | 848B | |
+34.11% | 627B | |
-3.66% | 363B | |
+15.06% | 318B | |
+9.18% | 299B | |
+11.86% | 234B | |
+15.29% | 225B | |
+15.67% | 179B | |
+2.47% | 167B |
- Stock Market
- Equities
- EBS Stock
- News Emergent BioSolutions Inc.
- Emergent BioSolutions to Look for M&A